Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2011002012 - MEDICINAL AGENT COMPRISING COMBINATION OF SGLT1 INHIBITOR AND INSULIN-RESISTANCE-AMELIORATING AGENT

Publication Number WO/2011/002012
Publication Date 06.01.2011
International Application No. PCT/JP2010/061127
International Filing Date 30.06.2010
IPC
A61K 31/7056 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
7056containing five-membered rings with nitrogen as a ring hetero atom
A61K 31/40 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 3/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
A61P 3/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
CPC
A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/7056
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
7056containing five-membered rings with nitrogen as a ring hetero atom
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
Applicants
  • キッセイ薬品工業株式会社 KISSEI PHARMACEUTICAL CO., LTD. [JP]/[JP] (AllExceptUS)
  • 加藤 浩 KATO, Hiroshi [JP]/[JP] (UsOnly)
  • 中村 俊哉 NAKAMURA, Shunya [JP]/[JP] (UsOnly)
Inventors
  • 加藤 浩 KATO, Hiroshi
  • 中村 俊哉 NAKAMURA, Shunya
Agents
  • 田中 光雄 TANAKA, Mitsuo
Priority Data
2009-15728501.07.2009JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) MEDICINAL AGENT COMPRISING COMBINATION OF SGLT1 INHIBITOR AND INSULIN-RESISTANCE-AMELIORATING AGENT
(FR) AGENT THÉRAPEUTIQUE COMPRENANT UNE COMBINAISON D'UN INHIBITEUR DE SGLT1 ET D'UN AGENT D'AMÉLIORATION DE LA RÉSISTANCE À L'INSULINE
(JA) SGLT1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬
Abstract
(EN)
A medicinal agent useful for the treatment of hyperglycemia-related diseases, which comprises a combination of 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H- pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2- dimethylpropionamide, which has an inhibitory activity on SGLT1 (sodium-dependent glucose cotransporter 1), or a pharmacologically acceptable salt thereof and an insulin-resistance-ameliorating agent.
(FR)
L'agent thérapeutique ci-décrit, utile pour le traitement des maladies liées à l'hyperglycémie, comprend une combinaison d'un 3-(3-{4-[3-(β-D-gluco- pyranosyloxy)-5-isopropyl-1H- pyrazol-4-ylméthyl]-3-méthylphénoxy}- propylamino)-2,2-diméthylpropionamide ayant une activité inhibitrice sur SGLT1 (sodium-dependent glucose cotransporter 1), ou d'un sel pharmacologiquement acceptable de celui-ci, et d'un agent d'amélioration de la résistance à l'insuline.
(JA)
SGLT1(ナトリウム依存性グルコース共輸送体1)阻害活性を有する3-(3-{4-[3-(β-D-グルコピラノシルオキシ)-5-イソプロピル-1H-ピラゾール-4-イルメチル]-3-メチルフェノキシ}プロピルアミノ)-2,2-ジメチルプロピオンアミド又はその薬理学的に許容される塩と、インスリン抵抗性改善薬とを組み合わせてなる、高血糖症に起因する疾患の治療に有用な医薬を提供する。
Also published as
Latest bibliographic data on file with the International Bureau